K Number
K080437
Device Name
MICRUS MICROCOIL SYSTEM, DELTAPAQ 10 CERECYTE, MODEL CDF
Date Cleared
2008-05-08

(83 days)

Product Code
Regulation Number
882.5950
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The Micrus Microcoil Delivery System is intended for endovascular embolization of intracranial aneurysms, other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae, and are also intended for arterial and venous embolizations in the peripheral vasculature.
Device Description
The Micrus Deltapaq 10 Cerecyte Microcoil Systems consists of an embolic coil ("Microcoil") attached to a Device Positioning Unit (DPU) (single use, sterile)
More Information

Not Found

No
The summary describes a physical medical device (microcoil delivery system) and does not mention any software, algorithms, or AI/ML capabilities.

Yes
The device is intended for endovascular embolization of various vascular abnormalities, which is a therapeutic intervention.

No

Explanation: The device is an embolic coil system used for endovascular embolization, a therapeutic procedure, not a diagnostic one. Its intended use is to treat abnormalities by blocking blood flow, not to identify or characterize them.

No

The device description explicitly states that the system consists of an embolic coil and a Device Positioning Unit (DPU), which are physical components, not software.

No, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • Intended Use: The intended use clearly states "endovascular embolization of intracranial aneurysms, other neurovascular abnormalities... and are also intended for arterial and venous embolizations in the peripheral vasculature." This describes a therapeutic procedure performed within the body to treat a medical condition.
  • Device Description: The device is described as an "embolic coil" attached to a "Device Positioning Unit." This is a physical device used for a medical intervention.
  • Lack of IVD Characteristics: An IVD is a medical device used to perform tests on samples taken from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening. This device does not perform any such tests on biological samples.

The device described is a therapeutic medical device used for embolization, which is a procedure to block blood vessels.

N/A

Intended Use / Indications for Use

The Micrus Microcoil Delivery System is intended for endovascular embolization of intracranial aneurysms, other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae, and are also intended for arterial and venous embolizations in the peripheral vasculature.

Product codes

HCG

Device Description

The Micrus Deltapaq 10 Cerecyte Microcoil Systems consists of an embolic coil ("Microcoil") attached to a Device Positioning Unit (DPU) (single use, sterile)

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Intracranial, neurovascular, arterial and venous peripheral vasculature.

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Not Found

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s)

K033813

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 882.5950 Neurovascular embolization device.

(a)
Identification. A neurovascular embolization device is an intravascular implant intended to permanently occlude blood flow to cerebral aneurysms and cerebral ateriovenous malformations. This does not include cyanoacrylates and other embolic agents, which act by polymerization or precipitation. Embolization devices used in other vascular applications are also not included in this classification, see § 870.3300.(b)
Classification. Class II (special controls.) The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance Document: Vascular and Neurovascular Embolization Devices.” For availability of this guidance document, see § 882.1(e).

0

K080437

1/1

Summary of Safety and Effectiveness

| Submitter Name and
Address: | Micrus Endovascular Corp.
821 Fox Lane
San Jose, CA 95131 |
|------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Contact Name: | Patrick Lee
MAY - 8 2008
Phone: 408-433-1428
Fax: 408-433-1585
Email: plee@micruscorp.com |
| Preparation Date: | February 22, 2008 |
| Device Name and
Classification: | Micrus Microcoil System
Common Name: Occlusion Coil
Trade Name: Micrus "Deltapaq 10 Cerecyte" Microcoil System
catalog # CDF
Classification Name: Device, Neurovascular Embolization
Regulatory Class II |
| Predicate Devices: | Micrus Cerecyte Microcoil, 510(k) no. K033813 |
| Device Description: | The Micrus Deltapaq 10 Cerecyte Microcoil Systems consists of an
embolic coil ("Microcoil") attached to a Device Positioning Unit
(DPU) (single use, sterile) |
| Device Intended Use | The Micrus Microcoil Delivery System is intended for endovascular
embolization of intracranial aneurysms, other neurovascular
abnormalities such as arteriovenous malformations and
arteriovenous fistulae, and are also intended for arterial and venous
embolizations in the peripheral vasculature |

Comparison to Predicate Device:

The Micrus Deltapaq 10 Cerecyte Microcoil System has shown substantial equivalence to the Micrus Cerecyte Microcoil System in terms of intended use, design, material of construction, implant dimensions including wire dimensions, coil dimensions, coil pitch, and coil stiffness. The Deltapaq 10 Cerecyte microcoils use the same packaging, method and material of construction, and sterilization method as its predicate. The modification has not altered the fundamental technology of the sponsor's predicate device Conclusion:

Based upon the design, materials, function, intended use, comparison with currently marketed devices and the non-clinical testing performed by Micrus Endovascular Corporation, it is concluded that the Micrus Deltapaq 10 Cerecyte Microcoil System is substantially equivalent to the predicate device in safety and effectiveness.

1

Image /page/1/Picture/1 description: The image shows the seal of the U.S. Department of Health & Human Services. The seal features a stylized eagle-like symbol on the right side. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES. USA" is arranged in a circular pattern around the symbol.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

MAY - 8 2008

Micrus Endovascular Corporation % Mr. Patrick Lee Regulatory Affairs Specialist 821 Fox Lane San Jose, California 95131

Re: K080437

Trade/Device Name: Micrus Microcoil Delivery Systems Regulation Number: 21 CFR 882.5950 Regulation Name: Neurovascular embolization device Regulatory Class: II Product Code: HCG Dated: April 2, 2008 Received: April 4, 2008

Dear Mr. Lee:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Isting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

2

Page 2 - Mr. Patrick Lee

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket, Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours.

Mark N Mulhausen

Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

3

Micrus Microcoil Delivery System 510(k) Premarket Notification

K080437

Indications for Use

510(k) Number (if known):

Device Name:

Micrus Microcoil Delivery Systems

080437

Indications For Use:

The Micrus Microcoil Delivery System is intended for endovascular embolization of intracranial aneurysms, other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae, and are also intended for arterial and venous embolizations in the peripheral vasculature.

Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR

Over-The-Counter Use (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

764 RPQh fix nkm

(Division Division of General, Restorative, and Neurological Devices

510(k) Number K080437

Page 1 of

Micrus Endovascular Corporation